Daxor (DXR) investor relations material

Company overview and mission

• Focused on optimal fluid management through blood volume analysis across healthcare settings.

• Operates a 20,000 sq ft R&D and production facility in Oak Ridge, Tennessee.

• Vertically integrated, producing analyzers and up to 200,000 test kits annually.

• Employs a razor-and-blades business model, with recurring revenue from test kits.

• Targets a broad range of conditions where blood volume management is critical, including heart failure and critical care.

Technology and clinical impact

• Volumex is an FDA-approved radiopharmaceutical diagnostic for direct blood volume measurement.

• Over 75,000 tests shipped, used in 100+ medical centers, with 170+ peer-reviewed studies supporting efficacy.

• New rapid, portable analyzer launched, replacing older systems and enabling easier deployment.

• Easy BVA Lab model allows remote sample processing, expanding access without on-site equipment.

• Studies show up to 86% reduction in 1-year mortality and 56% reduction in 30-day readmissions for heart failure patients.

Market opportunity and commercial strategy

• Addressable market includes 7 million heart failure patients and millions more in critical care and hypertension.

• Test is reimbursed by Medicare and private insurers for both inpatient and outpatient use.

• Commercial focus expanding to cardiology, nephrology, oncology, and private practices.

• Recent capital raise of $9 million supports sales team expansion and commercialization.

• Strategic partnerships with Defense Health Agency, NIH, and MedAxiom to drive adoption.